Articles tagged with Cancer Medication
ABT-737, a BH3 mimetic, targets Bcl-2 proteins to induce apoptosis in cancer cells. The treatment has shown effectiveness against acute myeloid leukemia (AML) cells and can be combined with MCL-1 inhibitors for improved results.
Researchers have found that a new anti-cancer drug, BB-10901, is well-tolerated at higher doses than previously used, with patients responding to treatment and experiencing durable complete responses. The drug targets cancer cells expressing CD56, leading to clinical activity and stable disease in some patients.
Researchers found that combining imantanib with apoptosis-inducing drugs inhibits tumor growth more effectively than either therapy alone. The combination increased sensitivity to TRAIL, a drug that induces cell death, leading to reduced pulmonary metastases and primary tumor growth.
A MEK enzyme inhibitor has shown long-lasting stable disease in patients with advanced solid cancers, inhibiting key targets and reducing cell proliferation. Phase II trials have been initiated for melanoma, pancreatic, lung, and colon cancers.
Inhibiting cyclin D1, a gene present in excessive amounts in half of breast cancers, improves cell-killing effects of radiation. Flavopiridol was found to add to ionizing radiation's effects without toxicity, using zebrafish models.
Researchers at Thomas Jefferson University have found a nanoparticle that can protect normal tissue from radiation damage as effectively as standard drugs. The nanoparticle, called DF-1, acts like an oxygen sink, binding to dangerous oxygen radicals and reducing their production.
A new anti-cancer drug has shown promise for halting the progression of advanced solid tumors by blocking aurora proteins. In a phase I clinical trial, seven patients experienced disease stabilization, with four remaining stable for over seven months.
Researchers developed a novel method to produce small chemicals from symbiotic bacteria found in sea squirts, which have anticancer properties. The ability to manipulate these chemicals using genetic pathways opens possibilities for developing new cancer and HIV treatments.
Researchers are evaluating the use of Aricept to prevent cognitive decline and memory problems in pediatric brain cancer survivors who have received cranial radiation. The study, which will enroll 35 patients ages 8-17, aims to assess whether the drug can help maintain baseline cognitive abilities and social relationships.
Researchers are using bacteria to manufacture a library of potential anti-cancer drugs, including analogues of streptorubin B, which could be more powerful than current synthetic options. The approach combines biology and organic synthesis to create complex structures.
Researchers found that a man's PSA velocity, or rate of increase in PSA levels, can accurately predict tumor aggression and danger. Men with lower PSA velocity have a 92% chance of not dying from prostate cancer within 25 years.
Researchers at UT Southwestern Medical Center have identified a gene, uPAR, responsible for metastases in early-stage breast cancer and poor prognosis. The study suggests that targeting the uPAR gene could be an effective strategy to stop or slow disease progression.
Researchers at the University of Manchester have made a breakthrough in developing a new class of cancer drugs that target the Aurora B enzyme, which helps cells divide and can lead to uncontrolled cell growth in cancer. Early clinical trials suggest the drug's toxicity is mild, offering a revolutionary new way to treat cancer.
The University of Liverpool, Royal Liverpool University Hospital and Clatterbridge Centre for Oncology are merging to create a cancer research centre, enabling global clinical trials of new therapies. The centre will be funded by Cancer Research UK and will double the number of patients in early phase clinical trials.
The Berkeley Cancer Genome Center will use genome analysis to identify genetic changes involved in cancer. The center aims to analyze messenger RNA populations and exon-specific expression to understand cancer development.
Researchers at the University of Virginia are exploring how nutrients in broccoli prevent cancer by bonding with a specific enzyme. This enzyme is linked to inflammatory diseases and cancer, and understanding its role could lead to anti-cancer compounds.
Yale University and NFCR have established a research center to design and discover new anti-cancer drug treatments. The center will focus on developing beta-peptide inhibitors that can target abnormal protein-protein interactions, which are often present in cancer cells.
A new approach uses mouse tests to predict which chemotherapy drugs work best for each patient, offering a promising way to individualize therapy earlier in treatment. The method involves implanting tiny bits of patient tumor into mice, allowing researchers to test multiple drugs simultaneously.
Researchers at UT Southwestern Medical Center have discovered a mechanism by which cancer cells become resistant to a specific class of drugs, hemiasterlin. A mutation in a single protein renders the drug ineffective and also makes the worms resistant to several other anti-cancer drugs.
A Phase II trial of Revlimid found that over 75% of MDS patients reduced their need for transfusions, with two-thirds completely freed from transfusions. In 45% of cases, no detectable cancer was found after treatment.
Acute myelogenous leukemia (AML) patients who have multiple active molecular pathways in their blood and bone marrow samples tend to have a poorer prognosis. Targeting just one pathway is unlikely to be effective due to cross-activation, requiring the development of multi-drug therapies.
Research highlights the increased risk of suicide among breast cancer survivors for up to 30 years after diagnosis, as well as the association between hormone therapies and ovarian cancer risk. Additionally, high levels of circulating sex hormones may contribute to premenopausal breast cancer risk.
Researchers studying a lancelet, a tiny primitive fish found in Tampa Bay waters, have identified key immune system proteins that share similarities with those found in humans. The study's findings could lead to improved biodefense and biotechnology for cancer treatment and disorders like rheumatoid arthritis.
Researchers have discovered aspirin's ability to prevent blood vessel formation, a crucial step in tumor growth. By targeting this process, scientists can develop entirely new types of cancer-fighting drugs.
A study found that Tadalafil (Cialis) significantly improved erectile dysfunction in prostate cancer patients who underwent 3D-CRT. Successful intercourse rates were 48% for those taking Tadalafil, compared to 9% for placebo group.
Researchers found that a defective version of the NPRL2 tumor suppressor gene makes lung cancer cells resistant to cisplatin, a common chemotherapy drug. Gene therapy targeting this gene may restore sensitivity to cisplatin, offering new hope for treating resistant lung cancer.
A Stanford study finds that the cancer drug Gleevec, used to combat leukemia and gastrointestinal cancers, may also be effective in treating rheumatoid arthritis. The researchers tested Gleevec on mice with a condition similar to human rheumatoid arthritis and found it almost completely prevented disease development.
A new genetic 'roadmap' tool connects human diseases with potential drugs, revealing potential applications in cancer and other diseases. The Connectivity Map uses genomic signatures to predict molecular actions of novel therapeutic compounds and suggest ways existing drugs can be newly applied.
Researchers have unveiled a new systematic approach to drug discovery that matches diseases with potential treatments using gene signatures. The 'Human Connectivity Map' allows scientists to compare disease signatures with those of treated cells, identifying effective treatments for cancer, obesity and Alzheimer's disease.
The journal features articles on integrative cancer therapies combining conventional and alternative medicine. It has generated significant media attention and will receive its first Impact Factor in 2008 Journal Citation Reports.
The Starr Cancer Consortium aims to coordinate research efforts among five renowned institutions to understand and treat cancer. The collaboration will focus on developing new technologies, diagnostic approaches, and treatments for various forms of the disease.
Researchers have found that a class of cancer drugs can restore skeletal muscle mass and prevent decline in muscular dystrophy. Treatment with histone deacetylase inhibitors like Trichostatin A improved muscle function and resistance to degeneration in dystrophic mice.
A potential diagnostic marker indicates anti-angiogenic drugs' effectiveness by measuring a decrease in circulating endothelial cells. Anti-angiogenic drugs target tumor blood vessels, starving them of oxygen and nutrients.
Researchers at Thomas Jefferson University have discovered a new way to sidestep gleevec resistance in leukemia cells. By reactivating the protein C/EBP-alpha, they found that leukemia development is halted. This discovery could lead to new treatment strategies for leukemias resistant to gleevec and other cancers.
Researchers at Salk Institute discover that cancer cells use NF-kB survival factor to stay alive when attacked by chemotherapeutic drugs. This finding suggests a strategy to enhance the effectiveness of rapamycin-based therapies by inhibiting NF-kB signaling.
Researchers are using the tiny fruit fly Drosophila to identify genes that impact on the spread of human cancer cells. By combining genetic screens with functional analysis in human cell culture models, they aim to discover novel proteins involved in cell migration and invasion.
A Purdue University researcher has shed light on the details of one mechanism by which targeted drug therapy is achieved. The understanding of how to deliver and unload a cancer drug can be extrapolated to other diseased cells, including those involved in arthritis, multiple sclerosis, and Crohn's disease.
V. Craig Jordan's research has led to breast cancer prevention drugs like tamoxifen and raloxifene; the new grant aims to develop a treatment model to reverse resistance to anti-estrogen therapy, facilitating access to new breast cancer therapeutic drugs.
A study found that cyclin D1 gene overexpression is associated with better survival outcomes and increased sensitivity to the cancer-fighting drug bortezomib in breast cancer patients. This is because it suppresses the activity of another gene, STAT3, which promotes cell growth and prevents tumor cells from dying.
A study led by Pasi Jänne found that a single mutation in the EGFR protein can cause drug resistance in non-small cell lung cancer. The investigation demonstrated that even tiny quantities of this mutation can lead to resistance, challenging current treatment strategies.
Researchers at Ohio State University have discovered how a chemotherapy drug aids an anti-cancer virus in targeting brain tumors. The study found that the drug slows immune cells' activity, allowing the virus to spread and kill more cancer cells. This may lead to new treatment options for incurable human brain tumors.
Researchers have identified a genetic profile indicating chromosomal instability as predictive of clinical outcome in various cancer types. This signature was found to predict poor clinical outcome in 12 populations studied, making it a potential diagnostic tool for identifying aggressive cancers.
Finasteride increases PSA testing's ability to detect prostate cancer with higher sensitivity and accuracy, according to a study published in the Journal of the National Cancer Institute. The study found that men taking finasteride had improved PSA test performance compared to those taking a placebo.
A new study finds that drinking carbonated soft drinks is not linked to esophageal cancer or cardia adenocarcinoma. Additionally, bortezomib has been shown to inhibit the growth of neuroblastoma cells, a childhood tumor type.
A study found that 9.9% of chemotherapy medications for children with acute lymphoblastic leukemia were prescribed or administered incorrectly. The errors may have put patients at risk of relapse or overdose-related complications.
A new experimental RNA-based drug has been shown to kill prostate cancer cells by targeting specific genes and inducing cell death. The treatment, developed at Duke University Medical Center, was tested in mice and found to shrink tumor size by half without causing any side effects.
Researchers discovered a key component in the insulin pathway that contributes to metabolic syndrome and insulin resistance. The study found that reducing this gene's function can lower glucose and lipid levels and even extend lifespan.
Researchers discovered that JAK/STAT signaling can change the genetic packaging of DNA, leading to the activation of previously silenced genes and contributing to cancer. This finding suggests a new mechanism for cancer development and has implications for cancer treatment.
A phase III study found that adding topotecan to standard chemotherapy for ovarian cancer does not increase overall survival or reduce cancer recurrence. The treatment instead leads to more blood-related toxicities and infections.
A Phase III clinical trial at St. Jude Children's Research Hospital shows that erythropoietin (EPO) increases hemoglobin levels in anemic children with cancer, reducing the need for red blood cell transfusions and improving their quality of life.
MDM2 overproduced leads to unbalanced p53 regulation, promoting cancer cell growth. The study identifies protein fragments binding to MDM2, inhibiting its destructive effect on p53.
Researchers found that tamoxifen does not significantly reduce mortality in women at lower risk of breast cancer. For high-risk women, taking tamoxifen can be expensive with a $1.3 million price tag per year of life saved in the US market.
A new study finds that tamoxifen has little impact on mortality rates for most high-risk women, with life expectancy improving only at higher breast cancer risks. The high cost of tamoxifen further reduces its utility as a cancer prevention drug in the US.
A study by Thomas Force and his team found that Gleevec, a 'miracle' cancer drug, can cause heart failure in patients with CML due to its effect on the Abelson tyrosine kinase protein. The researchers also discovered that second-generation Gleevec drugs may have similar toxicities.
A team of researchers has designed tools to accelerate interpretation and potential use of human genome project information. The Joint Center for Molecular Modeling will support scientists in developing innovative software for improving protein structure prediction quality.
Researchers developed a new strategy to identify genetic mutations that drive cancerous growth by analyzing proteins instead of genes. This approach allows for rapid identification of molecular abnormalities vulnerable to specific drug treatments, enabling personalized medicine and potential targeted therapies.
Researchers at Thomas Jefferson University have identified proepithelin as a crucial protein in the spread of bladder cancer. The study found that proepithelin promotes migration and invasion of bladder cancer cells, suggesting it could be a potential target for new drugs.
Researchers at Ohio State University found that interleukin 21 boosts natural killer cell activity, attacking and destroying Herceptin-coated breast cancer cells. This could lead to increased patient response rates with the existing drug.
Researchers at the University of Pennsylvania School of Medicine used molecular imaging techniques to discover small molecule compounds that can restore normal p53 function in cancer cells, killing human tumor cells. The findings emphasize the growing role of imaging technology in individualized cancer treatments.
Researchers have developed an enzyme inhibitor that targets betaine-homocysteine-S-methyltransferase (BHMT), slowing cancer growth by reducing methionine production. The BHMT inhibitors show promise as a potential treatment for cancer, with the possibility of enhancing efficacy when combined with other drugs.